学术论文 | 研究方向 | 科研项目 | 招生计划
Jie Sun, Futao Chu, Jiani Pan, Yaxin Zhang, Lu Yao, Jiuan Chen, Li Hu, Juan Zhang, Ye Xu, Xiaojia Wang, Wenming Cao, Yuntao Xie. BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers,J Clin Oncol,41(5):991-999
Fan Zang, Xinyun Ding, Jiuan Chen, Li Hu, Jie Sun, Juan Zhang, Ye Xu, Lu Yao, Yuntao Xie*. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype,Breast cancer research and treatment,195: 431-9
Lu Yao, Jie Sun , Li Hu, Jiuan Chen, Juan Zhang, Ye Xu, Yuntao Xie. Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants,Journal of human genetics,67(11)：639-642
Single-cell RNA sequencing reveals the cellular origin and evolution of breast cancer in BRCA1 mutation carriers.,Cancer Res,81(10):2600-2611
Yonghai Guo, Qiting Wan, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Yuntao Xie. Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients,Breast,10;65: 55-60
Jingsi Liu, Jiuan Chen, Jie Sun, Lu Yao, Juan Zhang, Yuntao Xie, Ye Xu. Low Expression of PALB2 is Associated With Poor Survival in Chinese Women With Primary Breast Cancer,Clin Breast Cancer,2023 Jun;23(4):e259-e266
Jiaming Liu, Lu Yao, Jie Sun, Li Hu, Jiuan Chen, Juan Zhang, Ye Xu, Yuntao Xie. Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer,Cancer Biol Med,20(2):147-154
Xuejing Liu, Yanjie Wang, Kun Cao, Lu Yao, Li Hu, Jie Sun, Juan Zhang, Ye Xu, Yuntao Xie. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants,Breast Cancer Res Treat.,199(1):25-33.
Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.,Int J Cancer,148(4):941-949
Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.,Breast Cancer Res Treat,174 (3):639-647.
Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.,J Cancer Res Clin Oncol,145(5):1235-1242
Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.,Int J Cancer,146(2):487-495
Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients.,Cancer Sci,110 (10):3368-3374
Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negativebreast cancer patients.,Breast Cancer Res Treat,2020;179(3):605-614.
Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers in a Large Cohort of Unselected Chinese Breast Cancer Patients.,Int J Cancer,2020;146(12):3335-3342.
BRCA1 c.5470_5477del, a Founder Mutation in Chinese Han Breast Cancer Patients.,Int J Cancer,2020;146(11):3044-3052
Li Hu, Jie Sun, Zhongwu Li, Ziwei Qu, Yan Liu, Qiting Wan, Jiaming Liu, Xinyun Ding, Fan Zang, Juan Zhang, Lu Yao, Ye Xu, Yin Wang, and Yuntao Xie*. Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients,NPJ breast cancer,8: 52
Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.,JAMA Netw Open,4(4):e216259
乳腺癌易感基因RECQL致瘤机制及潜在分子靶点的研究, 课题负责人, 2020.1.1～2023.12.31, 国家自然科学基金委员会面上项目
科技北京百名领军人才培养工程, 课题负责人, 2016.1.1～2018.12.31, 北京市科委 LJ201629